Regeneron (REGN) PT Raised to $664 at Leerink Partners; Reacceleration in Eylea

Regeneron (REGN) PT Raised to $659 at Brean Capital

Brean Capital analyst Jonathan Aschoff reiterated a Buy rating and boosted his price target on Regeneron Pharma (NASDAQ: REGN) to $659.00 (from $525.00) following solid Q1 results, led by US Eylea sales of $655 million, which overwhelmingly beat consensus of $571 million.

Regeneron commented, ". Sales growth comprised a 21% QoQ increase in underlying physician demand, with distributor inventory levels remaining within the normal 1-2 week range. Importantly, Regeneron... More

Regeneron Pharma's (REGN) Price Target Boosted to $665 at RBC

RBC Capital maintained an Outperform rating on Regeneron Pharma (NASDAQ: REGN) and raised its price target to $665.00 (from $570.00). Analyst Adnan Butt said the set up looks "ideal" for near and long-term outperformance.

"Eylea beat and guidance raise were substantial, driving nearterm gains. Mid-term... More

Regeneron Pharma's (REGN) Price Target Raised to $720 at Deutsche Bank

Deutsche Bank maintained a Buy rating on Regeneron Pharma (NASDAQ: REGN) and raised its price target to $720.00 (from $650.00). The change follows Q2 results. Analyst Robyn Karnauskas noted Eylea is still growing at 50% year-over-year.

"Just when street was thinking about potential stabilization of Eylea share, 2Q US numbers surprised... More

Regeneron (REGN) Tops Q2 EPS by 12c

Regeneron (NASDAQ: REGN) reported Q2 EPS of $2.89, $0.12 better than the analyst estimate of $2.77. Revenue for the quarter came in at $999 million versus the consensus estimate of $887.81 million.

Pipeline Progress

Regeneron has fifteen fully human monoclonal antibodies generated using the Company's VelocImmune® technology in clinical development, including five in collaboration with Sanofi(5). In addition to Praluent,... More